Document is current
Any future updates will be listed below
-
Authors
Witkowski, Marco
Wu, Yuping
Hazen, Stanley L.
Tang, W. H. Wilson https://orcid.org/0000-0002-8335-735X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00590200 at ClinicalTrials.govDocuments that mention this clinical trial
Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
https://doi.org/10.1186/s12933-021-01365-9
-
Funding
Funding for this research was provided by:
national heart, lung, and blood institute (P01HL147823, R01HL103866)
- License Information
-
More Information
Article History
Received: 23 June 2021
Accepted: 15 August 2021
First Online: 21 August 2021
Declarations
:
: The study complied with the principles of Good Clinical Practice rules. All participants gave written informed consent to a protocol that was approved by the Cleveland Clinic Institutional Review Board.
: All authors have read the final version and agreed to publish the manuscript.
: Dr. Hazen reports being named as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Dr. Hazen also reports being a paid consultant for Procter & Gamble, having received research funds from Procter & Gamble, and Roche Diagnostics, and being eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, a fully owned subsidiary of Quest Diagnostics, and Procter & Gamble. Dr. Tang has served as a paid consultant for Sequana Medical AG, Owkin Inc, Relypsa Inc, Cardiol Therapeutics Inc, preCARDIA Inc, Genomics plc, and received honoraria from Springer Nature and American Board of Internal Medicine, all unrelated to the present topic. The other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
